December 7, 2015
Project Summary
INNODIA is a large-scale EU-funded collaborative consortium aiming to accelerate translation from preclinical type 1 diabetes research to clinical interventions. The project unites leading experts in basic and clinical type 1 diabetes research, 4 pharmaceutical partners (Sanofi-Aventis Deutschland GMBH, Novo Nordisk A/S, GlaxoSmithKline Research & Development Ltd., and Eli Lilly Company Ltd.), and two major public research organizations (Breakthrough T1D and The Leona and Harry B. Helmsley Charitable Trust) to drive breakthroughs toward the prevention and cure of type 1 diabetes.
Key goals and approaches:
- Integrated consortium: Combines expertise in beta-cell biology, immunology, biomarker discovery, bioinformatics, systems biology, and clinical trial design.
- Access to populations and biobanks: Clinicians oversee T1D registries and recruit patients, at-risk relatives, and family members, enabling deep phenotyping and creation of a ‘living biobank.’.
- Clinical sample network: Standardized collection of diverse biological samples (blood, plasma, serum, urine, stool) for longitudinal studies.
- Translational focus: Coordinated studies of unique clinical samples and preclinical models aim to identify novel biomarkers and interventions, ready for testing in well-designed clinical trials.
- Patient and regulator collaboration: Ensures research is clinically relevant and accelerates translation into therapies.